The board of directors of Ocumension Therapeutics announced that the principal place of business of the Company in Hong Kong will be changed from "Room 1901, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong" to "Unit 417, 4th Floor, Lippo Centre, Tower Two, No.89 Queensway, Admiralty, Hong Kong" with effect from September 30, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.47 HKD | +7.83% | +8.92% | -3.14% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.14% | 573M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Therapeutics Announces the Change of Principal Place of Business, Effective September 30, 2023